A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1106-1115

  Palumbo, A ^a   Hauler, F ^a   Dziunycz, P ^b   Schwager, K ^a   Soltermann, A ^c   Pretto, F ^a   Alonso, C ^d   Hofbauer, G F ^b   Boyle, R W ^d   Neri, D ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

immunotherapy; monoclonal antibody; natural killer cells; photodynamic therapy; squamous cell carcinoma; tumour neovasculature

Indexed keywords

5 [4 (SUCCINIMIDE N OXYCARBONYL)PHENYL] 10,15,20 TRIS(4 N METHYLPYRIDIMIUMYL)PORPHYRIN TRICHLORIDE; ANTIBODY CONJUGATE; FIBRONECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L19; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; IRRADIATION; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOCONJUGATES; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY;

EID: 79953185350     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.78     Document Type: Article

References (55)

1. Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113(8): 2139-2145
2. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11(19, Part 2): 7053s-7063s (Pubitemid 41428704)
3. Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, Dreischaluck J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE (2009) Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 113(20): 5019-5027
4. Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D (1999) Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 231(1-2): 239-248 (Pubitemid 30394737)
5. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102(1): 75-85
6. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13): 4384-4392 (Pubitemid 37494099)
7. Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12(10): 3200-3208 (Pubitemid 43837370)
8. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9(6): 653-660 (Pubitemid 36749213)
9. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5): 1659-1665 (Pubitemid 34533039)
10. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 68(3): 397-405 (Pubitemid 26384145)
11. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3): 754-758 (Pubitemid 34525533)
12. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6(7): 535-545 (Pubitemid 43980542)
13. Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Invest Drugs 7(6): 522-528 (Pubitemid 43891030)
14. Chen WR, Adams RL, Higgins AK, Bartels KE, Nordquist RE (1996) Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: an in vivo efficacy study. Cancer Lett 98(2): 169-173 (Pubitemid 26010325)
15. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116(2): 304-313 (Pubitemid 40967270)
16. Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, Kosmehl H, Zardi L, Neri D, Neri P (2006) Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 118(7): 1805-1813 (Pubitemid 43376447)
17. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5): 391-400 (Pubitemid 38618122)
18. Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1-18 (Pubitemid 43261975)
19. Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119(9): 2205-2212 (Pubitemid 44423682)
20. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N (1981) In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127(1): 34-38 (Pubitemid 11075445)
21. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63(12): 3202-3210 (Pubitemid 36735873)
22. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20(3): 264-269 (Pubitemid 34205419)
23. Head M, Jameson MB (2010) The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Invest Drugs 19(2): 295-304
24. Heath VL, Bicknell R (2009) Anticancer strategies involving the vascu-lature. Nat Rev Clin Oncol 6(7): 395-404
25. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96(8): 1159-1165 (Pubitemid 46625071)
26. Hofbauer GF, Bouwes Bavinck JN, Euvrard S (2010) Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 19(6): 473-482
27. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275(5299): 547-550 (Pubitemid 27051913)
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342 (Pubitemid 38702844)
29. Josefsen LB, Boyle RW (2008) Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs 2008: 276109
30. Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 67(10): 4940-4948 (Pubitemid 46910202)
31. Korbelik M, Dougherty GJ (1999) Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res 59(8): 1941-1946 (Pubitemid 29186169)
32. Kuimova MK, Bhatti M, Deonarain M, Yahioglu G, Levitt JA, Stamati I, Suhling K, Phillips D (2007) Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem Photobiol Sci 6(9): 933-939 (Pubitemid 47313199)
33. Li WW, Hutnik M, Gehr G (2008) Antiangiogenesis in haematological malignancies. Br J Haematol 143(5): 622-631
34. Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R (2007) Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97(7): 888-894 (Pubitemid 47519312)
35. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5(6): 436-446 (Pubitemid 40791486)
36. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D (2002) Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 13(4): 729-736 (Pubitemid 34801114)
37. Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61(2): 711-716 (Pubitemid 32128637)
38. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753): 1510-1512 (Pubitemid 41746349)
39. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95(8): 2637-2644 (Pubitemid 30210544)
40. Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30(4): 487-490 (Pubitemid 35001582)
41. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58(20): 4646-4653 (Pubitemid 28480630)
42. 131I-L19SIP radioimmu-notherapy in Hodgkin lymphoma patients. Blood 113(10): 2265-2274
43. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009a) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113(10): 2275-2283
44. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009b) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12): 1718-1722
45. Siemann DW, Chaplin DJ, Walicke PA (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Invest Drugs 18(2): 189-197
46. Sutton JM, Clarke OJ, Fernandez N, Boyle RW (2002) Porphyrin, chlorin, and bacteriochlorin isothiocyanates: useful reagents for the synthesis of photoactive bioconjugates. Bioconjug Chem 13(2): 249-263 (Pubitemid 34267936)
47. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94(1): 192-198 (Pubitemid 29300149)
48. Thorpe PE, Brown AN, Bremner Jr JA, Foxwell BM, Stirpe F (1985) An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent anti-tumor effects in vitro and in vivo. J Natl Cancer Inst 75(1): 151-159 (Pubitemid 15005969)
49. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47(7): 1127-1135 (Pubitemid 47544908)
50. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2): 176-180 (Pubitemid 29072543)
51. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11): 2405-2413 (Pubitemid 351590471)
52. Wan S, Parrish JA, Anderson RR, Madden M (1981) Transmittance of nonionizing radiation in human tissues. Photochem Photobiol 34(6): 679-681
53. Yu J, Javier D, Yaseen MA, Nitin N, Richards-Kortum R, Anvari B, Wong MS (2010) Self-assembly synthesis, tumor cell targeting, and photo-thermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc 132(6): 1929-1938
54. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6(8): 2337-2342
55. Zuberbuhler K, Palumbo A, Bacci C, Giovannoni L, Sommavilla R, Kaspar M, Trachsel E, Neri D (2009) A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. Protein Eng Des Sel 22(3): 169-174